As of 2026-03-21, the Relative Valuation of Vanda Pharmaceuticals Inc (VNDA) is (60.21) USD. This relative valuation is based on P/E multiples. With the latest stock price at 7.12 USD, the upside of Vanda Pharmaceuticals Inc based on Relative Valuation is -945.6%.
The range of the Relative Valuation is (54.61) - (63.31) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 18.3x - 22.6x | 20.0x |
| Forward P/E multiples | 17.5x - 21.2x | 20.4x |
| Fair Price | (54.61) - (63.31) | (60.21) |
| Upside | -866.9% - -989.2% | -945.6% |
| Date | P/E |
| 2026-03-20 | -2.39 |
| 2026-03-19 | -2.88 |
| 2026-03-18 | -2.87 |
| 2026-03-17 | -2.89 |
| 2026-03-16 | -2.96 |
| 2026-03-13 | -2.96 |
| 2026-03-12 | -3.12 |
| 2026-03-11 | -3.12 |
| 2026-03-10 | -3.21 |
| 2026-03-09 | -2.91 |
| 2026-03-06 | -2.65 |
| 2026-03-05 | -2.65 |
| 2026-03-04 | -2.75 |
| 2026-03-03 | -2.63 |
| 2026-03-02 | -2.74 |
| 2026-02-27 | -2.99 |
| 2026-02-26 | -2.89 |
| 2026-02-25 | -2.78 |
| 2026-02-24 | -2.74 |
| 2026-02-23 | -2.73 |
| 2026-02-20 | -1.93 |
| 2026-02-19 | -2.05 |
| 2026-02-18 | -2.02 |
| 2026-02-17 | -2.08 |
| 2026-02-13 | -2.04 |
| 2026-02-12 | -2.05 |
| 2026-02-11 | -2.49 |
| 2026-02-10 | -2.49 |
| 2026-02-09 | -2.52 |
| 2026-02-06 | -2.54 |
| 2026-02-05 | -2.43 |
| 2026-02-04 | -2.55 |
| 2026-02-03 | -2.70 |
| 2026-02-02 | -2.60 |
| 2026-01-30 | -2.53 |
| 2026-01-29 | -2.61 |
| 2026-01-28 | -2.58 |
| 2026-01-27 | -2.69 |
| 2026-01-26 | -2.61 |
| 2026-01-23 | -2.69 |
| 2026-01-22 | -2.72 |
| 2026-01-21 | -2.66 |
| 2026-01-20 | -2.59 |
| 2026-01-16 | -2.51 |
| 2026-01-15 | -2.50 |
| 2026-01-14 | -2.58 |
| 2026-01-13 | -2.50 |
| 2026-01-12 | -2.49 |
| 2026-01-09 | -2.46 |
| 2026-01-08 | -2.46 |